Substance / Medication

Infigratinib

Overview

Active Ingredient
infigratinib
RxNorm CUI
2550729

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Cure after surgery for hepato-pancreato-biliary cancers: A systematic review.
Maspero Marianna, Sposito Carlo, Mazzaferro Vincenzo et al. · Dig Liver Dis · 2025
PMID: 39004554Meta-Analysis
Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis.
Angelico Roberta, Bonaccorsi Riani Eliano, De Martin Eleonora et al. · Liver Transpl · 2025
PMID: 39347698Meta-Analysis
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman Andrew B, Sepúlveda-Sánchez Juan Manuel, Cloughesy Timothy F et al. · Clin Cancer Res · 2022
PMID: 35344029TrialFull text (PMC)
Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
Hartley Iris R, Roszko Kelly L, Li Xiaobai et al. · JBMR Plus · 2022
PMID: 35991529TrialFull text (PMC)
Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.
Magone M Teresa, Hartley Iris R, Fitzgibbon Edmond et al. · Ophthalmology · 2021
PMID: 32888946TrialFull text (PMC)
Infigratinib in patients with advanced cholangiocarcinoma withgene fusions/translocations: the PROOF 301 trial.
Makawita Shalini, K Abou-Alfa Ghassan, Roychowdhury Sameek et al. · Future Oncol · 2020
PMID: 32580579Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Infigratinib (substance)
SNOMED CT
1162483003
UMLS CUI
C3254591
RxNorm CUI
2550729

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.